Jia Chen

Jia Chen

Auto-generated profile, based on publicly available information

Jia Chen


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 January 2026 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
GJGuiping Jiang
Guiping Jiang
JCJia Chen
Jia Chen
YTYongzhong Tang
Yongzhong Tang
XLXing Liu
Xing Liu
PKPang Ke
Pang Ke
LZLei Zhou
Lei Zhou
Objective: Globally, the burden of drug use– and high‐BMI–associated hepatocellular carcinoma is increasing, yet systematic epidemiological assessments and risk factor analyses remain inadequate. This study aims to utilize Global Burden of Disease (GBD) data and genetic epidemiological methods to evaluate trends in the disease burden of drug use– and high‐BMI–associated hepatocellular carcinoma, identify potential risk factors, and predict future burden through machine learning models, thereby providing evidence for clinical prevention and precision interventions. Methods: Drawing from the GBD 2021 database, we extracted data on liver cancer deaths, disability‐adjusted life years (DALYs), years lived with disability (YLDs), and years of life lost (YLLs) from 204 countries and regions between 1990 and 2021, conducting stratified analyses by sex, age, and SDI region. Two‐sample Mendelian randomization (MR) was employed to assess potential causal relationships between 14 lifestyle factors and liver cancer. Furthermore, an XGBoost predictive model was constructed, combined with SHAP analysis to identify key influencing factors, and disease burden projections were made for 2022–2050. Results: In 2021, drug use–related liver cancer caused 65,499 deaths globally, while high‐BMI–related liver cancer caused 46,204 deaths, with annual average growth rates of 2.39% and 3.02%, respectively, between 1990 and 2021. Regions with high sociodemographic index (SDI) bore the greatest absolute burden, though regions with low SDI exhibited higher growth rates. MR analysis suggested a potential genetic association between alcohol consumption and hepatocellular carcinoma. The XGBoost model projected that without interventions, the burden of drug us– and high‐BMI–related hepatocellular carcinoma would continue to rise through 2050. SHAP analysis revealed age, sex, and time as key factors influencing disease burden. Conclusion: The global burden of drug use– and high‐BMI–related hepatocellular carcinoma continues to rise, particularly in middle‐ and high‐SDI regions. Integrating genetic epidemiology with machine learning methods provides data support for identifying high‐risk populations, enabling early intervention and precision prevention. This approach facilitates clinical translation and public health policy formulation.